tiprankstipranks
Trending News
More News >
Suzuken Co Ltd (JP:9987)
:9987

Suzuken Co (9987) AI Stock Analysis

Compare
0 Followers

Top Page

JP:9987

Suzuken Co

(9987)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
¥6,387.00
▲(2.27% Upside)
Suzuken Co's overall stock score reflects a strong balance sheet and moderate valuation, but is tempered by significant revenue decline and cash flow challenges. Technical indicators suggest a stable market position, but the lack of earnings call data and corporate events limits further insights.

Suzuken Co (9987) vs. iShares MSCI Japan ETF (EWJ)

Suzuken Co Business Overview & Revenue Model

Company DescriptionSuzuken Co., Ltd. is a leading Japanese healthcare company primarily engaged in the distribution of pharmaceuticals, medical devices, and related healthcare products. Founded in 1946, the company operates in various sectors, including pharmaceutical wholesale, healthcare logistics, and the development of healthcare information systems. Suzuken is known for its extensive network and strong relationships with healthcare providers, enabling it to cater to the needs of hospitals, clinics, and pharmacies across Japan.
How the Company Makes MoneySuzuken generates revenue primarily through the wholesale distribution of pharmaceutical products, which constitutes the bulk of its sales. The company has established a comprehensive supply chain, enabling efficient delivery and logistics services to healthcare institutions. Key revenue streams include the sale of prescription medications, over-the-counter drugs, and medical devices. Additionally, Suzuken earns income from its healthcare information systems by providing software solutions that improve operational efficiencies for healthcare providers. Strategic partnerships with pharmaceutical manufacturers and healthcare organizations further enhance its revenue potential, as these collaborations can lead to exclusive distribution agreements and innovative product offerings.

Suzuken Co Financial Statement Overview

Summary
Suzuken Co's financial performance is marked by a strong balance sheet with low leverage and effective equity utilization. However, the sharp decline in revenue growth and cash flow issues are significant concerns that need addressing to ensure liquidity and operational sustainability.
Income Statement
75
Positive
Suzuken Co's income statement shows a stable gross profit margin of around 8% over the years, indicating consistent cost management. The net profit margin has improved slightly, reaching 1.44% in the latest year, reflecting better profitability. However, the revenue growth rate has turned negative at -45.2%, which is a significant concern. EBIT and EBITDA margins have shown slight improvements, suggesting operational efficiencies.
Balance Sheet
80
Positive
The balance sheet of Suzuken Co is strong, with a very low debt-to-equity ratio of 0.0044, indicating minimal leverage and financial risk. The return on equity has improved to 8.47%, showing effective use of equity to generate profits. The equity ratio is healthy, suggesting a stable financial structure with a good proportion of assets financed by equity.
Cash Flow
60
Neutral
Cash flow analysis reveals challenges, with negative operating and free cash flows in the latest period, indicating liquidity issues. The free cash flow to net income ratio is positive, suggesting that despite negative cash flows, the company is generating sufficient net income. However, the operating cash flow to net income ratio is negative, highlighting potential cash flow management issues.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.41T2.40T2.39T2.31T2.23T2.13T
Gross Profit192.18B192.23B185.25B179.69B167.33B157.84B
EBITDA49.42B62.38B51.40B39.48B32.55B22.92B
Net Income33.32B34.50B29.02B20.34B14.39B7.89B
Balance Sheet
Total Assets1.15T1.11T1.23T1.15T1.14T1.11T
Cash, Cash Equivalents and Short-Term Investments142.20B141.58B242.11B192.70B201.46B212.12B
Total Debt23.85B1.80B1.80B1.80B2.12B2.28B
Total Liabilities744.12B706.41B812.26B734.57B723.66B696.51B
Stockholders Equity402.16B407.29B416.31B411.21B417.69B417.05B
Cash Flow
Free Cash Flow0.00-83.73B71.58B19.53B-4.77B7.74B
Operating Cash Flow0.00-65.08B87.22B37.27B9.52B15.60B
Investing Cash Flow0.0020.38B10.35B-46.36B1.44B-14.59B
Financing Cash Flow0.00-35.48B-31.72B-26.22B-11.60B-7.39B

Suzuken Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6245.00
Price Trends
50DMA
5909.38
Positive
100DMA
5845.70
Positive
200DMA
5442.76
Positive
Market Momentum
MACD
73.43
Negative
RSI
64.97
Neutral
STOCH
93.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Positive. The current price of 6245 is above the 20-day moving average (MA) of 5984.35, above the 50-day MA of 5909.38, and above the 200-day MA of 5442.76, indicating a bullish trend. The MACD of 73.43 indicates Negative momentum. The RSI at 64.97 is Neutral, neither overbought nor oversold. The STOCH value of 93.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9987.

Suzuken Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$415.53B14.444.94%2.71%5.11%-20.51%
69
Neutral
$327.42B13.107.09%1.60%1.37%-1.55%
68
Neutral
$496.10B13.716.39%2.32%3.88%-10.72%
67
Neutral
¥58.09B6.384.40%2.23%72.07%
67
Neutral
¥353.87B21.580.40%15.81%27.05%
60
Neutral
¥307.02B14.391.79%2.31%19.86%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9987
Suzuken Co
6,245.00
1,621.61
35.07%
JP:2784
Alfresa Holdings
2,436.00
287.01
13.36%
JP:7459
Medipal Holdings
2,756.50
386.32
16.30%
JP:3151
Vital KSK Holdings, Inc.
1,319.00
228.25
20.93%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,723.00
442.26
13.48%
JP:8129
Toho Holdings Co., Ltd.
4,755.00
493.45
11.58%

Suzuken Co Corporate Events

Suzuken Co. Updates on November 2025 Share Repurchase
Dec 1, 2025

Suzuken Co., Ltd. announced the results of its share repurchase program for November 2025, where it repurchased 471,900 common shares for approximately ¥2.77 billion. This activity is part of a larger repurchase plan initiated in May 2025, aiming to buy back up to 5.2 million shares by March 2026, reflecting the company’s strategy to enhance shareholder value.

Suzuken Co. Completes Share Repurchase to Enhance Capital Flexibility
Nov 20, 2025

Suzuken Co., Ltd. announced the completion of a share repurchase, acquiring 187,900 common shares for approximately ¥1.09 billion through the ToSTNeT-3 system. This move is part of a broader strategy to maintain a flexible capital policy in response to changing business conditions, with a total of 3,116,400 shares repurchased so far, amounting to ¥17.59 billion.

Suzuken Co. Updates on Share Repurchase Progress
Nov 19, 2025

Suzuken Co., Ltd. announced the results of its recent share repurchase program, acquiring 195,500 common shares for approximately ¥1.15 billion between November 1 and November 19, 2025. This move is part of a broader strategy to repurchase up to 5.2 million shares by March 2026, aiming to enhance shareholder value and optimize capital structure.

Suzuken Co. Announces Share Repurchase Plan
Nov 19, 2025

Suzuken Co., Ltd. has announced a share repurchase plan, detailing the method and specifics of the repurchase. The company plans to buy back up to 240,000 common shares at a total cost of approximately ¥1.39 billion through the ToSTNeT-3 system on the Tokyo Stock Exchange. This move is part of a broader strategy to repurchase up to 5.2 million shares, representing 7.21% of the total shares outstanding, by March 2026. The repurchase aims to enhance shareholder value and optimize the company’s capital structure.

Suzuken Co. Reports Higher-than-Expected Profits Despite Sales Shortfall
Nov 13, 2025

Suzuken Co., Ltd. reported variances between its forecasted and actual consolidated financial results for the six months ending September 30, 2025. While net sales were slightly below expectations, operating and ordinary profits exceeded forecasts due to effective cost management and strategic initiatives. The profit attributable to owners of the parent was significantly higher than anticipated, driven by extraordinary gains from the sale of investment securities. The company maintains its earnings forecast for the fiscal year ending March 31, 2026.

Suzuken Co. Reports Mixed Financial Results for First Half of 2025
Nov 13, 2025

Suzuken Co., Ltd. reported its consolidated financial results for the six months ended September 30, 2025, showing a slight increase in net sales by 1.8% to ¥1,219,440 million. However, the company experienced a decline in operating profit by 0.8% and a significant drop in profit attributable to owners of the parent by 19.9%. The company’s equity-to-asset ratio decreased to 34.5% from 36.6% as of March 31, 2025. Despite these challenges, Suzuken maintains its annual dividend forecast and plans to commence dividend payments on December 10, 2025. The financial outlook for the fiscal year ending March 31, 2026, anticipates a 2.8% increase in net sales but a decline in operating and ordinary profit.

Suzuken Co. Reports October Share Repurchase Results
Nov 4, 2025

Suzuken Co., Ltd. has reported the repurchase of 539,400 of its own shares during October 2025, amounting to approximately ¥3.16 billion. This action is part of a larger share repurchase program announced in May 2025, which allows for the repurchase of up to 5.2 million shares by March 2026. The ongoing repurchase strategy is aimed at enhancing shareholder value and optimizing the company’s capital structure.

Suzuken Co. Records Extraordinary Gain from Securities Sale
Oct 15, 2025

Suzuken Co., Ltd. has announced an extraordinary gain from the sale of investment securities, amounting to ¥15,567 million, as part of a strategic review and reduction of its cross-shareholdings. This gain will be recorded in the financial results for the fiscal year ending March 31, 2026, but it will not affect the company’s earnings forecast as the impact has already been accounted for.

Suzuken Co. Reports September 2025 Share Repurchase Results
Oct 1, 2025

Suzuken Co., Ltd. announced the results of its share repurchase for September 2025, acquiring 358,400 common shares for approximately ¥2.15 billion through market purchases on the Tokyo Stock Exchange. This repurchase is part of a larger plan, announced in May 2025, to buy back up to 5.2 million shares by March 2026, aiming to enhance shareholder value and optimize capital structure.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 30, 2025